BiotechTube
Home/Nurix Therapeutics/H. Matthew (Matt) Solomon
HM

H. Matthew (Matt) Solomon

Chief Financial Officer

Nurix Therapeutics

Therapeutic Areas

OncologyAutoimmune Diseases

Nurix Therapeutics Pipeline

DrugIndicationPhase
Bexobrutideg (NX-5948)Relapsed/Refractory B-cell MalignanciesPhase 1a/1b
NX-2127Relapsed/Refractory B-cell MalignanciesPhase 1a
NX-1607Oncology & Autoimmune IndicationsPhase 1
NX-0479Immuno-inflammatory DiseasesPhase 1
NX-0451Solid TumorsPreclinical
NX-0370Solid TumorsPreclinical
NX-0290Solid TumorsPreclinical

Leadership Team at Nurix Therapeutics

AT
Arthur T. Sands
President, CEO & Founder
GM
Gwenn M. Hansen
Chief Scientific Officer
SH
Stephanie Hua
Chief Legal Officer & Corporate Secretary
JR
John R. (Jack) Murphy
Chief Business Officer
View full Nurix Therapeutics profile